Latest News

Davis Viprakasit, MD, FACS, discusses advanced cystoscopy training for APPs and the importance of collaboration between APPs and urologists to expand patient care.

A national cohort study found that metabolic syndrome and its components were frequently documented within the first year of concurrent ADT and ARPI therapy for prostate cancer.

Clinicians across four cities weigh ARASEC and ARANOTE trial data, drug interactions, and access barriers in mCSPC treatment decisions.

María Natalia Gandur Quiroga, MD, MSc, highlights treatment selection, negative trials, and implementation in GU oncology as 3 key themes emerging from ASCO 2026.

The phase 2 MODeFIRe-1 trial will evaluate investigational MRT-2359 plus apalutamide in AR-mutated metastatic castration-resistant prostate cancer.

Water vapor thermal therapy also provided greater QoL improvement vs combination pharmacotherapy while preserving sexual function.

Urology practices should prepare for more than a simple payment cut in 2027, according to Jonathan Rubenstein, MD; and Mark Painter.

Kari Tikkinen, MD, PhD, discusses POISE-3 findings showing tranexamic acid reduced major bleeding without significantly increasing thrombotic events in urologic surgery.

Susanne Quallich, PhD, ANP-BC, NP-C, discusses APP leadership, specialization, professional growth, and expanding the role of APPs in urology.

Scott Bauer, MD, ScM, discusses an N-of-1 trial showing heterogeneous responses to long-term tamsulosin, identifying older men who may be candidates for deprescribing.

The designations were based on preliminary clinical data with 68Ga-NYM096, including a small, multicenter study presented at ASCO 2026.

Hans Arora, MD, PhD, discusses how communication and collaborative leadership can strengthen teamwork and performance in the operating room.

The phase 2 RadiCaL trial found that adding radium-223 to cabozantinib did not improve skeletal event-free survival in metastatic renal cell carcinoma.